Aptimmune Biologics is mucosal vaccine company developing novel swine vaccines aimed at combating the growing threat of PRRSV and influenza virus—estimated at an annual combined economic impact of $1.4 billion on the U.S. swine industry. Aptimmune’s new vaccine portfolio will change the management of these diseases, and significantly improve swine health and producer productivity.

Aptimmune Biologics is headquartered in Champaign, IL.